by Mark Curtis | Aug 25, 2015
. Welcome to your update from the Clinic for the month of July. Adaptimmune moves a second candidate into the clinic. Ziopharm receives an Orphan Drug Designation for its cutting edge IL-12 technology. Canadian cell therapy company, Hemostemix, keeps moving forward...
by Mark Curtis | Aug 18, 2015
. Welcome to your Cell Therapy Deal Review for the month of July. Here at Signals we’ve decided to change the name of this monthly column, to pay consideration to the fact the majority of the technologies discussed here are cell-based. Moving forward, I will continue...
by Stacey Johnson | Aug 7, 2015
. First female scientists were #DistractinglySexy – and hilarious, I might add. (If this means nothing to you, I recommend you read this article for a good recap.) Now their female engineering friends and colleagues are also tackling sexism in STEM – science,...
by Mark Curtis | Jul 29, 2015
. Welcome to your Regenerative Medicine Deal Review for the month of June. It was an epic month in partnerships that saw multiple collaborations closely tying industry leaders together. Almost all public cell-based immunotherapy companies have formed partnerships with...
by Stacey Johnson | Jul 24, 2015
. You are probably ready for something more substantial from Right Turn after three weeks of light vacations posts. I have something that fits the bill. Greg Bonfiglio, Founder and Managing Partner of Proteus Venture Partners, was interviewed by PharmaTelevision in...
Comments